АБАнастасия Борисовна Богомолова

Анастасия Борисовна Богомолова

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Анастасия Борисовна Богомолова has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Surgical correction of resistant cervical dystonia: evolution of methods and current trends (a systematic review)

    by E. A. Chizhova, V. V. Gusev, A. B. Bogomolova

    Cervical dystonia (CD) is the most common form of focal dystonia, characterized by abnormal head posture, chronic pain, and significant reduction in quality of life. Botulinum toxin therapy is the first — line standard, but 10–30 % of patients develop resistance or insufficient response, necessitating effective surgical alternatives. Objective — to analyze the evolution, efficacy, and safety of all known surgical methods for cervical dystonia to optimize clinical decision — making. Material and methods. A systematic literature analysis was performed using PubMed, Scopus, eLibrary, and Cochrane Library databases covering the period 1960–2026. Results. Three main surgical eras were identified: destructive (thalamotomy, pallidotomy), peripheral denervation (Bertrand’s operation with modifications), and neuromodulation — deep brain stimulation (DBS). A network meta — analysis of 55 studies (2032 patients) demonstrates superiority of DBS in the degree of improvement (mean difference 7.03–10.71 points on the TWSTRS scale) and safety profile compared to selective peripheral denervation (SPD). Conclusion. Deep brain stimulation of the globus pallidus internus (GPi) or subthalamic nucleus (STN) is the current gold standard for resistant forms of CD. SPD remains relevant as a less expensive and technically accessible alternative in resource — limited settings.

  • Open Access

    Cognitive Impairments and the Possibility of Their Correction in Patients with Muscular Dystonia

    by Вадим Венальевич Гусев, Анастасия Борисовна Богомолова

    Introduction. Modern scientific literature frequently reports impairments in cognitive abilities in patients with muscle dystonia. However, there is still no consensus regarding their pharmacological correction. To find a potential solution to this problem, the authors of this study evaluated the effect of botulinum therapy on cognitive changes in patients with muscle dystonia. The aim of the study was to assess cognitive abilities in patients with muscle dystonia before and after botulinum therapy. Materials and methods. The study involved 28 patients of both sexes diagnosed with muscle dystonia, who received two injections of botulinum toxin at a 4-month interval. A comparative analysis was conducted of the muscle dystonia severity scores on the TWSTRS scale and cognitive abilities on the MoCA scale, obtained before and after botulinum therapy. Statistical data processing was performed using an application software package with standard algorithms of variation statistics. The Student’s t-test was used for comparing variables. Differences were considered statistically significant at p < 0.010. Results and discussion. The study revealed a statistically significant positive effect of botulinum therapy on both assessed parameters: the severity of muscle dystonia decreased by an average of nearly 30.0 %, and the patients’ cognitive abilities improved by an average of 14.5 %. The obtained data suggest a direct link between motor and cognitive functions. Thus, the use of botulinum toxin drugs in the therapy of muscle dystonia with concomitant cognitive impairments may be clinically justified and promising. Conclusions. The potential for using botulinum toxin not only as a muscle relaxant but also for the targeted correction of cognitive impairments in patients with muscle dystonia has been identified. These results open new prospects for the comprehensive rehabilitation of such patients and require further investigation within the framework of long-term follow-up observation.

  • The effectiveness of using a centrally acting muscle relaxant in combination with botulinum toxin injections in patients with spasmodic torticollis

    by V.V. Gusev, E.A. Makarov, O.A. Lvova, A.B. Bogomolova

    Objective. To analyze the efficacy of eperison in combination with botulinum toxin injections for the treatment of pain syndrome in patients with spastic torticollis (ST). Material and methods. A retrospective study was conducted to evaluate the effectiveness of eperison administration alongside botulinum therapy in 29 patients diagnosed with ST. The study employed a cross-sectional retrospective analysis of medical data. Patients receiving botulinum toxin injections at three-month intervals (a total of 6 cycles), with assessments at 2 months (4—6 cycles after each injection), were administered eperison at a dose of 150 mg/day. The efficacy of the treatments was evaluated using a validated scale: the 85-point TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale), assessed three times—before each botulinum injection (on day 1), at day 14, and and at day 60 later. Results. For cycles 1—3 (botulinum toxin, without eperisone), the average TWSTRS scale score on the on day 1 of each cycle was 40.72 — 41.66; cycles 4—6 with the addition of Eperisone — 26.6—30.4 points. When comparing the average values of the TWSTRS scale for cycles 1—3 and cycles 4—6 on the «Pain» scale, t-test value was: 15.85 (p=0.000546). Conclusion. The intake of the centrally acting muscle relaxant eperison resulted in a statistically significant improvement in patients with ST by the time of the next injection (paired Student’s t-test 2.77—2.92, p=0.05), including improvements in the «Pain» scale, compared to botulinum therapy without eperison in the same patients.